Pfizer Inc PFE

$30.00 -0.67 (-2.18%)

Valuation

Market cap
173,954,048,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.82
P/E (forward)
10.17
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
52,790,656
Avg volume
31,970,018
Day's range
$29.89 – $31.06
Shares out
5,699,674,000
Stochastic %K
80%
Beta
0.32
Analysts
Hold
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Cedenmo Nov 3, 11:10 PM
$PFE business is viable, dividend close 6% and reaffirmed, I’m up 20%. No complaints.
0 replies
cmhuff Nov 3, 10:51 PM
$PFE just rolling out a $30.5 covered call a week a time.
0 replies
MrPeanutEsquire Nov 3, 9:40 PM
$PFE Typical action for an earnings miss. I have never owned or even seen a more consistently backwards stock
1 replies
StocLatepG Nov 3, 9:18 PM
$PFE 36.83 one time
0 replies
KevinohWarsh Nov 3, 9:12 PM
$ANET I would love a 190 here and I can really cash in now that my $PFE sucks Ass and lost 5k
1 replies
svb64 Nov 3, 9:01 PM
$PFE lets see this after a couple more trading days. Its alwa's amazing to watch an unliked stock react to excellent earnings, revenues and outlook. Falling immediately after as short term traders dont get what they expect...and then after a couple days starts to rise.... Patience
1 replies
Biostonk23 Nov 3, 8:55 PM
$PFE need some changes … long overdue
0 replies
DrMcSavage Nov 3, 8:53 PM
$PFE great time to buy long calls- earnings report was overall great with guidance raised
0 replies